Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.46 |
| ▸ | PTAFR | P25105 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 3/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096886 | 0.83 | ESR1 (0.36) | SETD7PTAFRKCNH2ABHD6ESR1 | |
| SCHEMBL3965754 | 0.81 | AHR (0.34) | SETD7AHRESR1ESR2 | |
| SCHEMBL490256 | 0.78 | SETD7 (0.76) | SETD7KCNH2AHR | |
| SCHEMBL5097386 | 0.78 | PDK2 (0.52) | SETD7RAB9A | |
| SCHEMBL5097385 | 0.78 | PDK2 (0.52) | SETD7RAB9A | |
| SCHEMBL5091095 | 0.71 | PGR (0.38) | KDM1A | |
| SCHEMBL11573091 | 0.71 | SETD7 (0.76) | SETD7KCNH2AHR | |
| SCHEMBL5091006 | 0.71 | ESR1 (0.36) | SETD7PTAFRKCNH2ABHD6ESR1 | |
| SCHEMBL5905649 | 0.70 | SETD7 (0.60) | SETD7PTAFRFNTAFNTB | |
| SCHEMBL11574288 | 0.69 | SETD7 (0.52) | SETD7KCNH2AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20060135522-A1 | Tricyclic delta-opioid modulators | CARSON JOHN R | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135522-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | SETD7 4197/4885PTAFR 1317/4885KCNH2 618/4885 |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | SETD7 4197/4885PTAFR 1317/4885KCNH2 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.